Clinical Trial Update: Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fluzoparib with or without apatinib in platinum-sensitive relapsed ovarian cancer previously treated with PARP inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Adenocarcinoma of the Ovary
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Guangxi Medical University | Conditions: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Status: UNKNOWN